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Effect of valproate and pregabalin on
human anxiety-like behaviour in a
randomised controlled trial
Dominik R. Bach1,2,3, Christoph W. Korn1,2,4, Johanna Vunder1,2 and Antonia Bantel1,2
Abstract
Valproate is an anticonvulsant drug with strong preclinical evidence for reducing anxiety behaviour in rodents but no
clear clinical evidence. To motivate clinical trials, we here investigate the use of valproate in a translational human
model of anxiety behaviour. In a double-blind, randomised, placebo-controlled trial, n= 118 healthy participants
played a previously validated approach/avoidance conﬂict computer game to measure anxiety-like behaviour, while
under 400 mg valproate, under 200 mg of the established anxiolytic/anticonvulsant pregabalin, or under placebo.
Saccadic peak velocity and subjective ratings were assessed to control for drug-induced sedation. Compared to
placebo, valproate and pregabaline were anxiolytic in the primary outcome, and several secondary outcomes.
Bayesian model comparison decisively demonstrated no differences between the two drugs. Subjective and objective
sedation was signiﬁcantly more pronounced under pregabalin than valproate, but did not explain anxiolytic effects.
We demonstrate acute anxiolytic properties of valproate in healthy humans. Both drugs have similar anxiolytic
properties at the doses used. Valproate is less sedative than pregabalin. Our results suggest clinical trials on the use of
valproate in anxiolytic treatment. More generally, we propose a strategy of screening drugs in human preclinical
models that can directly be compared across species, such as the approach/avoidance conﬂict computer game used
here. This approach could thus facilitate translational anxiety research.
Introduction
Rodent anxiety paradigms eliciting approach/avoidance
conﬂict are often used as preclinical models of anxiety
disorder1. They have successfully enabled screening and
development of acutely anxiolytic drugs such as a range of
benzodiazepines and other anticonvulsants, all of which
act via GABAergic pathways. Of the many non-
benzodiazepine drugs tested in rodents, few have made
it to the clinic2, and this calls for an improved strategy of
drug evaluation3,4. A discrepancy between pre-clinical and
clinical effectiveness could be due to limitations of the
rodent models, but also species differences in neuro-
transmitter systems and signalling pathways. Ideally,
research in preclinical human models with cross-species
comparability5,6, as comparative intermediate step, could
motivate, or discourage, the large-scale effort of clinical
drug testing.
Pregabalin is an example anticonvulsant that has, after
initial rodent experiments7, successfully been translated to
the clinic in various trials8–16. Valproate, on the other
hand, is not in standard clinical use for anxiety disorders17
despite strong evidence for its anxiolytic properties in
rodent tests18–26. It acts via a pathway different from
benzodiazepines19,20, and lacks potential for tolerance23,
indicating its feasibility for prolonged use. Beyond pilot
studies27, and trials with bipolar patients and comorbid
anxiety28,29, only one small randomised control trial
(RCT) exists for use in generalised anxiety disorder30. The
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current study sought to answer the question whether
valproate has similar acutely anxiolytic properties as
pregabalin in humans.
To this end, we capitalised on a preclinical human
anxiety model31. In this behavioural task, participants
forage for monetary tokens in successive epochs under
threat of a virtual predator that can take away all collected
tokens. This task explicitly pits approach toward rewards
(monetary tokens) against avoidance of punishment
(capture by predator and loss of previously collected
tokens). It thus shares features with several rodent anxiety
tests, which are sensitive to benzodiazepines and hippo-
campus lesions32. Our model is not intended to differ-
entiate individuals with or without anxiety disorder, but to
temporarily elicit anxiety behaviour in healthy humans. It
thus allows focusing on one, possibly transdiagnostic,
dimension of psychopathology, in line with calls for
abstraction from particular diagnostic frameworks33.
Normatively, as the number of collected tokens
increases over an epoch of our task, potential loss
increases, and participants should become more cautious
by retreating to the safe place. We have previously shown
that this intra-epoch adaptation of behaviour is reduced
under treatment with lorazepam34 as well as after hip-
pocampus31 and amygdala34 lesions. In our previous
studies we compared seven measures of intra-epoch
adaptation and found that presence in safe place best
separated lorazepam from placebo34, and also separated
patients with hippocampal31 and amygdala34 lesions from
control participants. Hence, presence in safe place was
chosen as primary outcome, and the linear drug × time
interaction as a priori contrast. We hypothesised that both
pregabalin and valproate would reduce the primary out-
come in the a priori contrast.
Materials and methods
Participants
Participants were recruited from the general population
(n= 119; 40 per placebo and pregabalin group, 39 in
valproate group). One participant in the pregabalin group
did not complete the study due to vomiting immediately
after drug ingestion, such that n= 118 individuals were
included in the ﬁnal analysis. The groups did not differ in
age, gender, or baseline personality measures (Table 1).
All participants were screened for physical and mental
health conditions by a physician (see Table S1 for inclu-
sion and exclusion criteria). The study was conducted in
accord with the Declaration of Helsinki and approved by
the governmental research ethics committee (Kantonale
Ethikkomission Zurich, KEK-ZH 2014-0647) and by the
Swiss Agency for Therapeutic Products (Swissmedic,
2016DR2060). All participants gave written informed
consent using a form approved by the ethics committee.
The study was pre-registered at the primary German
Clinical Trials Register (DRKS00010230) and at the Swiss
Federal Complementary Database (KOFAM;
SNCTP000001772), and conducted at the University of
Zurich between 09 June 2016 and 16 September 2016.
Power analysis
To determine required sample size, we conducted a
power analysis (using G*power35) based on our previous
study on lorazepam. This study revealed, in the planned
primary outcome and contrast for the present study, an
effect size estimate of partial η2= 0.0345, based on t=
5.34 and dfresidual= 798. The non-sphericity correction for
residual degrees of freedom in this error stratum was
Greenhouse–Geissers ε= 0.1174, and the average corre-
lation between data points from the same subject in this
error stratum was r= 0.5081. Based on these sample
values, to achieve 80% power at a type I error threshold of
α= 0.05, a sample size of n= 37 per group was needed.
We set our target sample size at n= 40 per group to allow
for attrition.
Table 1 Sample characteristics
Sex Placebo
group
Valproate
group
Pregabalin
group
p
20 male 20
female
20 male 19
female
20 male 19
female
Mean ± SD Mean ± SD Mean ± SD
Age 24.83 ± 4.22 23.97 ± 3.21 23.56 ± 3.17 0.28
STAI X1 34.00 ± 7.55 32.20 ± 5.50 33.27 ± 7.10 0.50
STAI X2 38.41 ± 6.74 37.56 ± 6.40 36.95 ± 6.99 0.63
BDI 3.78 ± 4.25 4.07 ± 3.85 3.67 ± 4.13 0.90
VAS overall 1.72 ± 1.95 1.76 ± 2.12 5.30 ± 2.71 <0.001*
VAS sedation 2.81 ± 2.75 3.12 ± 2.45 6.07 ± 2.83 <0.001*
VAS
stimulation
2.77 ± 2.89 2.33 ± 2.46 2.46 ± 2.22 0.74
VAS dizziness 0.92 ± 1.72 1.13 ± 1.72 4.74 ± 3.00 <0.001*
PSV pre 392.6 ± 79.8 391.0 ± 67.1 373.1 ± 79.1 0.46
PSV post 406.5 ± 66.7 393.9 ± 55.8 362.2 ± 69.9 0.009*
Threat rating 51.3 ± 9.8 55.7 ± 9.6 54.9 ± 10.1 0.10
Threat
preference
1.48 ± 0.78 1.54 ± 0.68 1.62 ± 0.67 0.68
STAI X1 trait anxiety score, STAI X2 state anxiety score, BDI depression score, VAS
visual analogue scale, administered immediately before the computer game, PSV
peak saccadic velocity from a saccade task before (pre) or after (post) the
computer game, Threat rating explicit rating of the wake-up probabilities
immediately after the computer game, averaged over the three predators (see
Table S5 for an analysis of the individual threat levels), Threat preference most
preferred threat level from three pair-wise comparisons (1: low, 2: medium, 3:
high), p p-value for the omnibus main effect from a 3-level (Placebo, Valproate,
Pregabalin) one-way ANOVA
See Table S6 for a covariate analysis accounting for the group differences in VAS
and PSV
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Study medication
Our study medication was 400 mg valproic acid (cor-
responding to 500mg sodium valproate), supplied in
powder form from Katwijk chemie bv (Katwijk, The
Netherlands), and 200 mg pregabalin, brand name Lyrica®
(Pﬁzer, Zurich). Study dose for valproate was based on the
recommended starting single dose (corresponding to half
a daily dose) to minimise side effects. Pregabalin dose was
based on previous work in healthy humans36,37 and within
the range of the manufacturer’s daily dose recommenda-
tion on the Swiss market for treatment of GAD
(150–600mg per day in 2–3 single doses). According to
manufacturers’ brochures, peak plasma concentrations
are reached at approximately 60–90min (valproate) and
60min (pregabalin) after oral administration; the drugs’
half-lifes are approximately 10 h (valproate) and 6.5 h
(pregabalin). A GMP-licensed pharmacy (Kantonsa-
potheke Zürich) manufactured four capsules per partici-
pant containing 4 × 100mg valproate, 1 × 200 pregabalin,
and 3×mannitol or 4×mannitol (placebo). The pharmacy
randomised and blinded the study medication, separately
for male and female participants. Randomisation code was
broken after the last participant completed the study, and
after all data were checked for consistency.
Procedure
Screening visit 1 (day −7 to day −1)
Exclusion criteria were checked via medical/psychiatric
examination, and blood/urine test (Fig. 1a, Supplemental
Methods).
Drug visit 2 (day 0)
Participants ﬁlled in the State-Trait Anxiety Inventory38
and Beck’s Depression Inventory39 before ingesting study
medication. During a 100-min metabolisation time, they
were kept under surveillance of study staff. Participants
spent this time ad libitum, and were allowed to eat snacks
but no meals. Next, we measured saccadic peak velo-
city40–42 (Supplemental Data), and participants ﬁlled in
visual analogue scales (VAS) to record subjectively per-
ceived overall drug effect (I feel substance effect), sedation
(I feel dazed/sleepy), stimulation (I feel activated/awake),
and dizziness (I feel dizzy). One hundred twenty minutes
after drug ingestions, they started playing the approach/
avoidance computer game, which lasted around 1 h.
Afterward, we again measured saccadic peak velocity.
Behavioural AAC paradigm
Participants completed 240 epochs of our previously
described AAC task31,34, presented using the MATLAB
toolbox Cogent (www.vislab.ucl.ac.uk). In each epoch,
participants collected monetary tokens on a 24 × 16 grid
under threat of being attacked by a predator, which
resulted in the loss of all tokens collected in the given
epoch (Fig. 1b). One corner of the grid was a safe place, in
which the predator could not attack. Location of the safe
place was randomised on each epoch.
Tokens
At all times, 10 tokens were uniformly distributed on
the grid, and every 2 s one of the tokens changed its
position randomly. Collected tokens were replaced on the
grid, and their number displayed above.
Predator
The predator was initially inactive in the corner diag-
onal to the safe place. The predator could become active
and chase participants any time. Colour of the frame
around the grid (blue, purple, orange) indicated three
distinct predator wake-up probabilities (0.2, 0.5, and 0.8),
which participants learned to distinguish. Participants
started either in the same place as the predator (which we
Fig. 1 Experimental design. a Study procedure. b Behavioural
approach-avoidance conﬂict (AAC) computer game. A human player
(green triangle) is foraging for tokens (yellow rhombi), which
contribute to ﬁnancial reimbursement at the end of the game. At any
time, 10 tokens are present and are replaced in random position when
collected. Collected tokens are shown in the upper left corner, above
the grid. Meanwhile, a predator (grey circle) is inactive in a corner of
the grid, and can attack the human player at any given time according
to three probabilities speciﬁed by the frame colour. To avoid being
caught by the predator, the player can seek shelter in a safe place.
Presence in the safe place constitutes the primary outcome measure.
The safe place is always diagonal to the initial predator position.
During the chase phase, when the predator wakes up, the frame
colour turns red. All tokens from this epoch are lost when the player is
caught
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term “active” condition) or in the safe place, opposite the
predator (which we term “passive” condition here).
Notably, all rounds entailed going out onto the grid to
collect tokens, and over the course of an epoch, behaviour
becomes comparable for the two conditions (see Fig. S1).
Movements on the grid
Participants coordinated their movements by pressing
the four computer keyboard arrow keys. No diagonal
movements were possible. Participants could move at a
maximum speed of 10 grid blocks per second. All three
predators had the same speed of 40 grid blocks
per second. Thus, participants could try to escape an
active predator by retreating to the safe place but the
predator moved four times faster, and thus escape was
only possible if participants were close to the safe place.
Epoch duration
Epochs lasted 3–15 s (drawn from a uniform distribu-
tion with steps of 1.7 s). There was a 3 s countdown with a
preview of the grid layout before each epoch, during
which the player could not move. This was meant to
facilitate orientation with respect to starting place/pre-
dator position. After the pre-determined epoch duration,
the predator either woke up, or the next epoch started.
240 epochs were divided into ﬁve blocks with short self-
paced breaks.
Post-task questions
Participants rated on a VAS (ranging from 0% to 100%)
the wake-up probability and wake-up latency of the three
different predators.
Bonus epoch
Finally, participants were given the choice to select the
predator that they would like to face in a ﬁnal bonus
round. The selection process entailed three consecutive
pair-wise comparisons between the predators.
Payment
At the end of the game, the average number of tokens
from nine randomly selected epochs, plus the bonus
epoch, was transformed into a monetary reimbursement
that was added to the constant show-up fee.
Outcome measures
Proportion of presence in safe place (the only grid block
which the predator could not enter) was chosen as pri-
mary outcome, and the linear drug × time interaction as a
priori contrast. As in previous studies31,34 we additionally
report six further measures as secondary outcomes,
Bonferroni-corrected for six comparisons: (1) distance (as
the crow ﬂies) from threat (i.e., from the predator), (2)
distance from nearest wall, (3) presence in safe quadrant
(i.e., the quarter of the grid surrounding the safe place),
(4) presence in threat quadrant (i.e., quarter of the grid
surrounding the predator position), (5) token collection,
and (6) speed when outside safe place. Note that in our
previous study on lorazepam, presence in safe quadrant
was chosen as primary outcome34. This choice had been
based on a preceding hippocampus lesion study31, but it
turned out that presence in safe place better separated
lorazepam from placebo34. As auxiliary measures, we
analyse latency to forage after epoch start, and latency to
ﬂight after predator wake-up; catch rates, and the average
number of tokens retained at the end of each epoch,
including the chase phase; subjectively rated wake-up
probabilities and wake-up times of the three different
predators, and participants’ preferences in pair-wise
comparison of the three predators.
Statistical analysis
We averaged participants’ positions on the grid within
1 s bins, and then averaged across epochs, for each par-
ticipant, each condition, and time bin. Since epoch
duration was variable, more data were available for earlier
than for later time bins. Our factorial design included a
between-subjects factor (Placebo/Valproate/Pregabalin)
and three within-subjects factors: threat level (wake-up
probability, low/medium/high), task (active/passive start),
and time (15 time bins of 1 s duration). For some mea-
sures (token collection and speed when on grid), some
participants had no data values in the ﬁnal time bins (as
they were in the safe place for all trials during these time
bins), and these time bins were removed for analysis. We
used the software package R (function aov) to perform full
multistratum repeated-measures ANOVA model with
Greenhouse–Geisser corrected degrees of freedom. We
report the following a priori contrasts: (valproate vs. pla-
cebo) × time, (pregabalin vs. placebo) × time. To test for
drug differences, we also assess the third, non-
independent contrast (pregabalin vs. valproate) × time.
To conﬁrm drug equivalence, we report a Bayesian model
comparison between a model with one predictor per drug,
and reduced (non-nested) model with one predictor for
placebo, and one for the two drugs. We compute Bayesian
information criterion (using the R function BIC) and
interpret an absolute BIC difference >6 as decisive43.
Code availability
All codes used to generate the results in this manuscript
are fully available from the authors.
Results
Two hours after ingesting valproate, pregabalin, or
placebo, participants performed the AAC computer game
(Fig. 1b). Both valproate and pregabalin signiﬁcantly
reduced the primary outcome (a priori contrasts:
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valproate: F (1, 185)= 7.56, p= 0.007, partial η2= 0.005;
pregabalin: F (1, 185)= 16.08, p= 0.001, partial η2=
0.010). Figure 2a shows that as intra-epoch time passed,
participants under placebo spent increasingly more time
in the safe place, and this linear change over time was
reduced in participants under both drugs.
In Bonferroni-corrected secondary outcomes, valproate
reduced loss adaptation in “distance from threat”, while
pregabalin reduced loss adaptation in “distance from
threat”, “presence in threat quadrant”, and “speed when
on grid” (Fig. 2b). Exploratory analyses of the other error
strata are summarised in Table 2. At the same time,
participants’ behaviour in the placebo group was generally
similar to the behaviour of healthy participants in our
previous reports (see Table S2 and Fig. S1).
Next, we directly compared the effect of pregabalin and
valproate in a further non-independent contrast (Table 2).
No signiﬁcant difference between the two drugs in their
Fig. 2 Effect of valproate and pregabalin on primary and secondary outcomes. Line graphs show evolution of outcome measures over 15 s
epochs, evaluated in 1 s time bins. Inset bar graphs reﬂect the a priori contrast and show estimated change over time (linear ﬁxed-effects coefﬁcients
± standard error) for the three conditions. Inset scatter plots show change over time for individual participants, estimated in single-participant models
ﬁtted post hoc; these have no relation to the statistical hypothesis test and are shown for illustrative purposes. a Proportion of time spent in the safe
place (see Fig. 1b) linearly increases over time, and this increase is reduced in participants under valproate or pregabalin as compared to placebo
(linear drug × time interaction, see Table 2). b Six secondary outcome measures. There is no signiﬁcant difference between the two drugs in any
measure, and Bayesian model comparison favours a model in which they have the same impact as compared to placebo. See Fig. S1 for a
comparison with lorazepam. VPA valproate, PGB pregabalin, PLC placebo. *: signiﬁcant linear drug × time interaction (for secondary outcomes after
Bonferroni correction)
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impact on linear time adaptation emerged. To demon-
strate drug equivalence, we then conducted a Bayesian
model comparison. For the a priori contrast in all out-
comes, model evidence decisively favoured a model with a
common predictor for both drugs (Table S3), i.e., there
was decisive evidence (BIC difference >6) for drug
equivalence.
In two performance measures, catch rates and average
number of tokens retained at the end of each epoch
(including chase phase), no signiﬁcant group difference
emerged (p > .1, Table S4). Thus, all participants max-
imised their token collection, but by doing so they used
slightly different strategies.
There was no group difference in explicit ratings of
predator probability, or preference for the three predators
(Table S4, all p’s > .1). After including these measures as
covariates (together with their time interaction) into the
initial model, the signiﬁcance of linear drug × time effects
remained unchanged (Table S5).
Next, we were concerned that drug-induced sedation
might explain the impact of the drugs on the primary and
secondary outcome measures. Latency to escape when the
predator woke up was different between the study groups
(p= .029; Table S4), possibly indicating anxiolysis or
sedation. Indeed, self-ratings of overall drug effect and
sedation were higher for pregabalin than placebo (Table 1,
Table 2 Comparison of placebo, valproate, and pregabalin
Presence in safe
place*
Distance from
threat
Distance from
walls
Presence in safe
quadrant
Presence in
threat quadrant
Tokens
per second
Speed when
on grid
F/t
p
F/t
p
F/t
p
F/t
p
F/t
p
F/t
p
F/t
p
Valproate −0.98 −0.58 1.10 −1.05 −0.19 1.27 1.28
.33 .56 .27 .29 .85 .21 .20
Pregabalin −1.11 −0.75 1.33 −0.61 0.62 1.13 1.60
.27 .46 .19 .54 .54 .26 .11
Valproate × threat
omnibus
3.43* 3.02 1.60 2.96 1.71 1.98 0.65
.041 .061 .21 .064 .19 .15 .51
Valproate × threat linear 2.49* 2.04 -1.57 1.95 −1.18 −1.51 −0.87
.01 .04 .12 .053 .24 .13 .39
Pregabalin × threat
omnibus
1.28 1.27 1.43 1.88 0.49 1.76 2.62
.28 .28 .24 .16 .59 .18 .08
Pregabalin × threat
linear
1.56 1.54 −1.67 1.88 −0.35 −1.78 −2.25
.12 .13 .10 .061 .73 .08 .03
Valproate × task −1.53 −0.98 −1.05 −1.38 0.98 -0.68 −0.88
.13 .33 .30 .17 .33 .50 .38
Pregabalin × task −1.26 −1.31 0.04 −1.04 1.39 1.37 −1.29
.22 .19 .97 .30 .17 .17 .20
Valproate × time
omnibus
0.86 0.75 1.09 0.70 1.43 0.38 0.59
.40 .50 .36 .55 .23 .75 .55
Valproate × time linear† −2.75* −2.87* 0.29 −1.97 2.40 −1.42 −0.97
.007 .005 .77 .050 .017 .16 .33
Pregabalin × time
omnibus
1.83 1.90 1.42 2.11 2.35 0.88 1.23
.17 .14 .23 .097 .074 .44 .29
Pregabalin × time
linear†
−4.01* −4.56* 0.24 −3.49* 3.80* −2.03 −2.93*
.001 <.001 .81 <.001 <.001 .044 .004
Pregabalin vs.
valproate × time linear‡
−1.25
.21
−1.68
.094
−0.05
.96
−1.52
.13
1.39
.17
−0.60
.55
−1.95
0.052
Valproate × threat ×
time omnibus
1.93 1.21 1.31 .91 0.64 0.87 1.12
.072 .30 .23 .52 .78 .60 .35
Valproate × threat ×
time linear
5.67* 3.85* −3.62* 0.60 −2.80* −2.03 −1.55
<.001 <.001 <.001 .55 .005 .04 .12
Pregabalin × threat ×
time omnibus
0.68 0.57 1.09 0.54 0.44 0.46 1.12
.67 .78 .37 .86 .93 .96 .35
Pregabalin × threat ×
time linear
3.04* 1.98 −3.17* 1.86 −0.14 −1.27 −3.29*
.002 .048 .002 .064 .89 .20 .001
Results are shown from a 3 (Group: Placebo, Valproate, Pregabalin) × 3 (Threat: Low, Medium, High) × 2 (Task: Active/Passive) × 15 (Time bins of 1 s each) ANOVA. The
table lists F-values for omnibus effects and signed t-values for polynomial contrasts and for the main effects of drug and task. p-values were computed using
Greenhouse–Geisser corrected degrees of freedom. Signiﬁcant p-values after Bonferroni correction (primary outcome: α= .05; secondary outcomes: α= .05/6 ≅ 0.008)
are marked with asterisk. Signs of t-values are coded as higher-dependent values for drug vs. placebo, higher levels of threat, later time points, and passive vs. active. *
primary outcome. † a priori contrasts. ‡ non-independent direct comparison of pregabalin and valproate in the a priori contrast (see also Fig. 2 and Fig. S1)
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overall: t (68)= 6.7, p < .001; sedation: t (77)= 5.2, p
< .001) or valproate (overall: t (71)= 6.4, p < .001; seda-
tion: t (74)= 4.9, p < .001). Furthermore, saccadic peak
velocity, a sensitive measure of drowsiness induced by
GABAergic drugs, was lower for pregabalin than placebo
(t (75)= 2.9, p= .005) or valproate (t (71)= 2.3, p= .033)
when measured immediately after the game (Table 1).
This is why we included all self-ratings (overall drug
effect, sedation, stimulation, dizziness) and saccadic peak
velocity before and after the game, into our model as
covariates, together with their time interaction. Sig-
niﬁcance of the a priori contrasts was unchanged in all
primary and all secondary outcome measures (Table S5).
In sum, although pregabalin appeared to induce relevant
sedation in self-ratings and objective measures, we found
no evidence that the impact of valproate and pregabalin
on loss adaptation in our task could be explained by
sedation.
Further exploratory analysis revealed that females
responded more strongly to pregabalin than males in
primary and one secondary outcome measures while there
was no such difference for valproate (Table S6). We note
our study was not powered to detect sex-speciﬁc drug
effects.
Finally, we sought to directly compare the drug doses
used here with the effect of 1 mg lorazepam in a previous
study34 (Table S7 and Fig. S1). All three drugs combined
showed an anxiolytic effect on primary outcome as well as
on “distance from threat”, “presence in safe quadrant”,
“presence in threat quadrant”, and “speed when on grid”.
Lorazepam turned out to have a signiﬁcantly stronger
effect than the other two drugs on primary outcome as
well as “distance from walls”, “tokens per second”, and
“speed when on grid”. In most of these measures, all three
drugs were (near-) signiﬁcantly different from placebo.
However, “distance from walls” (potentially measuring
thigmotaxis, relating to agoraphobia44) was pronouncedly
inﬂuenced by lorazepam and not by pregabaline or
valproate. Thus, it appears not only that the lorazepam
dose used was more anxiolytic than the pregabalin or
valproate dose, but also that the drugs may somewhat
differ in their speciﬁc pattern of anxiolytic inﬂuences.
Discussion
Valproate is acutely anxiolytic in various rodent tests18–
26 but evidence for its efﬁcacy in anxiety disorders is
limited to a pilot study30. To facilitate further clinical
research, we here performed an intermediate comparative
research step5 and asked whether valproate is acutely
anxiolytic in healthy humans. As a main ﬁnding, valproate
had an anxiolytic effect on the primary and one secondary
outcome measure. There was no signiﬁcant difference
between valproate and pregabalin in our a priori contrast
in any outcome measure. Bayesian model comparison
decisively showed equivalence of the two drugs. Thus, we
found no indication of an anxiolytic difference between
the two drugs, but sedative side effects were far more
pronounced under pregabalin than valproate. Notably,
pregabalin dose was chosen based on previous studies in
healthy humans36,37 and is in the range of the recom-
mended daily doses for treatment of GAD. To minimise
side effects, valproate dose was selected more cautiously
and is in the range of a half daily starting dose for epilepsy.
It is possible that higher doses of valproate have a stronger
anxiolytic action but would also elicit more sedative side
effects. At the doses used here (200 mg pregabalin, 400mg
valproate), a direct comparison with a previous study34
revealed that these drugs were less anxiolytic than 1mg
lorazepam. Furthermore, different from lorazepam, they
did not inﬂuence thigmotaxis, a behaviour sometimes
associated with agoraphobia44.
A previous RCT compared 3 × 500 mg valproate
(Depakine ® chrono) over 6 weeks with placebo for the
treatment of GAD in n= 74 patients30. This trial found
signiﬁcantly higher response rates (50% HAMD reduc-
tion) in valproate vs. placebo-treated patients. As a lim-
itation, placebo responses in this study were much lower
than in other studies, e.g., in many RCTs with pregabalin.
Until today, no larger phase II studies have been con-
ducted on valproate to replicate this pilot trial. While our
results suggest acutely anxiolytic properties of valproate,
the single-dose design used here is not directly compar-
able to prolonged treatment over several weeks or
months. Consequently, we cannot directly make state-
ments on clinical effectiveness, which will require new
clinical trials.
To test anxiolytic properties, we used our recently
established human approach/avoidance conﬂict para-
digm31,34,45,46. This paradigm is designed to reﬂect rodent
conﬂict test and is sensitive to anxiolytic action of lor-
azepam34. It is thus different from tests designed to elicit
anxiety feelings, such as public speaking anticipation, for
which no unambiguous demonstration of sensitivity to
benzodiazepines exists47. As a limitation, it is not clear to
what extent the precise pattern of benzodiazepine effects
in conﬂict tests reﬂects their clinical efﬁcacy. Thus, while
our approach is likely to reveal drugs that have effects
similar to benzodiazepines in our conﬂict test, they are
not guaranteed to have the same effect as benzodiazepines
in a clinical condition. This concern could possibly be
mitigated by investigating valproate in other preclinical
anxiety tests, particularly in tests that are conceptually
different from rodent approach/avoidance conﬂict. While
it has been noted that our task uses ﬁnancial incentives
rather than “real” threat48 (such as mild electric shocks or
unpleasant images and sounds49,50), its immersive nature
may be effective enough to create a situation comparable
with real threat. Speciﬁcally, it is the only presently
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available human approach-avoidance paradigm validated
with anxiolytic drugs and lesion models.
Our paradigm was designed to induce behavioural
strategies that resemble those seen in clinical anxiety
states, such as passive avoidance and behavioural inhibi-
tion. Because the diagnosis of anxiety disorders primarily
relies on patients’ introspective assessment, i.e., symptoms
rather than signs5, it would be useful to assess the feelings
induced in healthy persons while being engaged in the
task presented here, which was not the focus of the cur-
rent study. At the same time, it may be informative to
assess the behavioural strategies that GAD patients use in
our task.
Interestingly, the anxiolytic effects of lorazepam, preg-
abalin, and valproate are probably mediated via the
GABAergic system, but by different mechanisms of
action. Lorazepam, like other benzodiazepines, binds
allosterically to the GABA (A) receptor and thus increases
the impact of GABA51. The other two drugs increase
GABA levels, but by less well understood mechanisms52.
Pregabalin does not bind to GABA receptors but to the
α2δ-1 subunit of voltage-gated calcium channels, and this
binding is required for the anxiolytic properties of the
drug53. Valproate inhibits succinic semialdehyde dehy-
drogenase, such reducing the degradation of succinic
semialdehyde, which inhibits the GABA-degrading
enzyme GABA transaminase54,55. It also acts on non-
GABAergic transmission by inhibiting voltage-gated Na
channels, and several further mechanisms of action have
been speculated, including at the genomic level, but
without clear evidence for their relevance even in the
main indications for valproate, namely, epilepsy and
bipolar disorder55. Other antiepileptic drugs potentially
acting via GABA-mediated mechanisms are gabapentin,
vigabatrin, and tiagabin52, which are therefore candidate
drugs for future preclinical tests. Once the relevant
pathways mediating the anxiolytic action of pregabalin
and valproate are elucidated, this could lead to the
development of new anxiolytic compounds. We propose
all of these substances could be evaluated in our human
pre-clinical model, as this would render an investment
into large-scale clinical studies more feasible. One con-
cern sometimes raised with respect to rodent approach/
avoidance tests is their sensitivity to GABAergic but not
other anxiolytic substances such as antidepressants4.
Investigating the sensitivity of our human model to non-
GABAergic anxiolytic as well as non-anxiolytic substances
could facilitate the screening of new drugs.
Despite their well-known side effects and addiction
potential, benzodiazepines are still commonly prescribed
for GAD (e.g., estimated prescription rates in 2002 across
the US: 38%56) despite the availability of alternatives such
as SSRIs, pregabalin, and psychotherapy. While there may
be many reasons for this, it could indicate suboptimal
response rates to these alternative treatments. A meta-
analysis across different drug treatments found response
rates between 40 and 75%, with a mean of 55%57. Simi-
larly, a recent industry-sponsored combined analysis of
pregabalin trials found a response rate (at trial endpoint)
of around 60%58. This leaves signiﬁcant room for
improvement. It would be interesting whether patients
that do not respond to psychotherapy, pregabalin, or
SSRIs, could beneﬁt from valproate.
To summarise, our study demonstrates acutely anxio-
lytic properties of valproate in healthy humans, and thus
suggests a potential of this drug in the treatment of
anxiety disorders. More generally, we furnish a new
strategy for testing drugs in translational anxiety research,
by harnessing an intermediate comparative model in
healthy humans. This model is not supposed to distin-
guish individuals with our without anxiety disorders by
their behaviour in the test, but instead to temporarily
elicit a particular dimension of psychopathology in heal-
thy humans. Thus, a validation of this approach will be
the demonstration that effectiveness in the preclinical test
predicts clinical efﬁcacy. With this work, we hope to
advance clinical research on new treatments for anxiety
disorders.
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